Focused antithrombotic therapy: Novel anti-platelet salicylates with reduced ulcerogenic potential and higher first-pass detoxification than aspirin in rats

Journal of Laboratory and Clinical Medicine

Volumn 132, Issue 6, 1998, Pages 469-477

  Hung, Daniel Y ^a   Mellick, George D ^a   Masci, Paul P ^a   Whitaker, Alan N ^a   Whitehouse, Michael W ^a   Roberts, Michael S ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0032393491     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(98)90124-X     Document Type: Article

References (27)

1. The SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-9.
2. Lecomte M, Laneuville OJC, Dewitt DL, Smith WL. Acetylation of human prostaglandin endoperoxide synthase-2 by aspirin. J Biochem 1994;269:13207-15.
3. Gaskill HV, Sirinek KR, Levine BA. Prostacyclin gastric cytoprotection is dependent on mucosal blood flow. Surgery 1982;92:220-5.
4. Ligumsky M, Grossman MI, Kauffman GL. Endogenous gastric mucosal prostaglandins: their role in mucosal integrity. Am J Physiol 1982;242:G337-41.
5. Walus KM, Pawlik W, Konturek SJ. Prostacyclin-induced gastric mucosal vasodilation and inhibition of acid secretion in the dog. Proc Soc Exp Biol Med 1980;163:228-32.
6. Ali M, McDonald JWD, Theissen JJ, Coates PE. Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin. Stroke 1980;11:9-13.
7. Siebert DJ, Bochner F, Imhoff DM, Watts S, Lloyd JV, Field J, et al. Aspirin kinetics and platelet aggregation in man. Clin Pharmacol Ther 1983;33:367-74.
8. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984;311:1206-11.
9. Roberts MS, Joyce RM, McLeod LJ, Vial JH, Seville PR. Slow-release aspirin and prostaglandin inhibition. Lancet 1986;1:1153-4.
10. McLeod LJ, Roberts MS, Seville PR. Low-dose enteric-coated aspirin as an antiplatelet preparation. Aust NZ J Med 1988;148:207.
11. Harris PA, Riegelman S. Influence of the route of administration on the area under the plasma concentration-time curve. J Pharmacol Sci 1969;58:71-5.
12. Cossum PA, Roberts MS, Kilpatrick D, Yong AC. Distribution and metabolism of nitroglycerin and its metabolites in vascular beds of sheep. J Pharmacol Sci 1986;75:731-7.
13. Iwamoto K, Takei M, Watanabe J. Gastrointestinal and hepatic first-pass metabolism of aspirin in rats. J Pharm Pharmacol 1982;34:176-80.
14. Wientjes MG, Levy G. Nonlinear pharmacokinetics of aspirin in rats. J Pharmacol Exp Ther 1988;245:809-15.
15. Hung DY, Mellick GD, Prankerd RJ, Roberts MS. Synthesis, identification, characterization, protein binding and stability of ester derivatives of salicylic acid and diflunisal. Int J Pharmacol 1997;153:25-39.
16. Rainsford KD, Whitehouse MW. Anti-ulcer activity of a slow-release zinc complex, zinc monoglycerolate (Glyzinc). J Pharm Pharmacol 1992;44:476-82.
17. Whitehouse MW, Orr KJ, Beck FW, Pearson CM. Freund's adjuvants: relationship of arthritic induction and adjuvanticity in rats to vehicle composition. Immunology 1974;27:311-30.
18. Spriggs AL. An albumin gradient method for separating the different white cells of blood, applied to the concentration of circulating tumor cells. Nature 1960;188:863.
19. Shen J, Wanwimolruk S, Wilson PD, Seddon RJ, Roberts MS. A clinical trial of a slow-release formulation of acetylsalicylic acid in patients at risk for preeclampsia. Br J Clin Pharmacol 1993;35:664-7.
20. Patrono C, Ciabattoni C, Pinca E. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980;17:317-27.
21. Hung DY, Mellick GD, Roberts MS. The effect of protein binding on the hepatic first pass of O-acyl derivatives of salicylates. J Pharm Pharmacol 1998;50:63-9.
22. Mellick GD, Roberts MS. The disposition of aspirin and salicylic acid in the isolated perfused rat liver: the effect of normal and retrograde flow on availability and mean transit times. J Pharm Pharmacol 1996;48:738-43.
23. Purves RD. Numerical estimation of the non-compartmental parameters variance (VRT) and coefficient of variation (CVRT) of residence times. J Pharmacol Sci 1994;83:202-5.
24. Richardson PD, Withrington PG. Liver blood flow (II): effects of drugs and hormones on liver blood flow. Gastroenterology 1981;81:356-75.
25. Vander AJ. Human physiology. 4th ed. New York: McGraw-Hill; 1986.
26. Roberts MS, Fraser S, Wagner A, McLeod L. Residence time distributions of solutes in the perfused rat liver using a dispersion model of hepatic elimination: 1. Effect of changes in perfusate flow and albumin concentration on sucrose and taurocholate. J Pharmacokinet Biopharm 1990;18:209-34.
27. Forster S, Buckton G, Beezer AE. The importance of chain length on the wettability and solubility of organic homologs. Int J Pharmacol 1991;72:29-34.